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Abstract
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive disorder characterized by the degeneration and
subsequent loss of upper and lower motor neurons, resulting in reduced muscle function and paralysis
(Mathis et al., 2017). Current therapies are limited to the oral administration of riluzole, which improves
survival by only 3 months (Mathis et al., 2017). Thus, new therapies are urgently required to treat this
neurodegenerative disorder.
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PERSPECTIVE
P2X7 receptor antagonism in 
amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive 
disorder characterized by the degeneration and subsequent loss 
of upper and lower motor neurons, resulting in reduced muscle 
function and paralysis (Mathis et al., 2017). Current therapies 
are limited to the oral administration of riluzole, which improves 
survival by only 3 months (Mathis et al., 2017). Thus, new thera-
pies are urgently required to treat this neurodegenerative disor-
der. Over the past decade, the intercellular signaling pathway in-
volving extracellular adenosine triphosphate (ATP) activation of 
the P2X7 receptor channel has emerged as a potential therapeutic 
target in ALS (Volonte et al., 2016). To this end, we evaluated 
recently whether the P2X7 antagonist, Brilliant Blue G (BBG), 
could alter disease progression in a murine model of ALS (Bartlett 
et al., 2017). In this model, mice overexpress a human variant of 
mutant superoxide dismutase 1 (SOD1G93A) and typically devel-
op clinical signs of ALS from day 70 or later depending on the 
laboratory, and the transgene copy number, gender and genetic 
background of the mice (Heiman-Patterson et al., 2005). Muta-
tions in the gene encoding SOD1 (including SOD1G93A) are asso-
ciated with 15–20% of familial ALS cases in humans, with human 
SOD1G93A transgenic mice being one of the most commonly used 
animal models of this disease (Heiman-Patterson et al., 2005).
In our study (Bartlett et al., 2017), intraperitoneal (i.p.) injec-
tion of BBG (45.5 mg/kg) into SOD1G93A mice 3 times per week 
from 62 days of age (late pre-onset) delayed weight loss and 
prolonged survival of female, but not male, mice. BBG treat-
ment also delayed weight loss in both genders combined. BBG 
treatment had no effect on clinical score or motor coordination 
in either gender, nor did it prevent motor neuron loss, micro-
gliosis, or affect the amount of lumber SOD1 or P2X7 protein at 
end-stage. Therefore, results from this study demonstrate that 
P2X7 antagonism with BBG has some therapeutic benefit in 
ALS, at least in female SOD1G93A mice. 
During the course of our pre-clinical trial (Bartlett et al., 
2017), two similar studies were published (Cervetto et al., 2013; 
Apolloni et al., 2014). These studies also reported some thera-
peutic benefit with BBG treatment in SOD1G93A mice, but with 
notable differences to our study (Figure 1). In the first of these 
studies (Cervetto et al., 2013), injection of BBG (45.5 mg/kg 
i.p.) every 2 days from day 90 (onset) improved motor coordi-
nation in mice of either gender, with greater improvement in 
male than female mice. BBG treatment also delayed weight loss 
in male and both genders combined, but not in female mice. 
BBG treatment did not alter survival. In the second of these 
studies (Apolloni et al., 2014), injection of BBG (50 mg/kg i.p.) 
3 times per week from day 100 (late pre-onset) improved motor 
coordination, but did not alter disease onset or survival, with 
no differences observed between genders. Injection of BBG (50 
mg/kg i.p.) 3 times per week from day 135 (onset) had no effect 
on motor coordination, disease onset or survival (Apolloni et 
al., 2014). SOD1G93A mice were also injected with a higher dose 
of BBG (250 mg/kg i.p.) 3 times per week from either day 40 
(asymptomatic), day 70 (pre-onset) or day 100 (late pre-onset) 
(Apolloni et al., 2014). BBG treatment from day 40 or 70 did not 
alter any observed disease parameter, but BBG treatment from 
day 100 delayed disease onset, and improved clinical score and 
motor coordination, but did not delay weight loss or prolong 
survival. BBG treatment from day 100 also increased motor 
neuron survival, and reduced microgliosis and pro-inflamma-
tory markers (nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase and interleukin-1β) at end-stage. As with 
treatment using BBG at 50 mg/kg, no differences were observed 
between genders with this compound at 250 mg/kg.
The effect of BBG treatment on the survival of female SOD-
1G93A mice in our study (Bartlett et al., 2017) paralleled the pro-
longed survival observed in female, but not male, heterozygous 
and homozygous P2X7 knockout (P2X7KO)/SOD1G93A mice 
compared to P2X7 wild-type (P2X7WT)/SOD1G93A mice (Apollo-
ni et al., 2013). In contrast, genetic ablation of P2X7 anticipated 
clinical onset, worsened disease progression and increased mo-
tor neuron loss, microgliosis, astrogliosis and pro-inflammatory 
markers (NADPH oxidase and inducible nitric oxide synthase) 
towards or at end-stage (Apolloni et al., 2013). Consistent with 
this, BBG treatment in our study caused an increase in pro-in-
flammatory marker serum monocyte chemoattractant protein-1 
in end-stage SOD1G93A mice (Bartlett et al., 2017), although 
group sizes were insufficiently powered to detect a significant 
difference. Together these two studies demonstrate a dual role 
for P2X7 activation in this model of ALS (at least in female 
SOD1G93A mice) by promoting disease progression but limiting 
aspects of neuroinflammation. Moreover, it may be of value to 
compare the effects of BBG treatment in P2X7WT/SOD1G93A and 
P2X7KO/SOD1G93A mice (which to the best of our knowledge 
has not been reported) to confirm P2X7 antagonism by BBG in 
SOD1G93A mice expressing functional P2X7.
Collectively the four studies discussed above (Apolloni et al., 
2013, 2014; Cervetto et al., 2013; Bartlett et al., 2017) reveal a 
complex role for P2X7 in the SOD1G93A murine model of ALS 
and by extension ALS in humans. The various and contrasting 
gender differences observed with P2X7 antagonism or genet-
ic ablation in these studies remain unexplained, but it is well 
known that disease progression in this model of ALS is gender 
dependent (Heiman-Patterson et al., 2005). It is noteworthy, that 
disease progression accelerates in ovariectomized SOD1G93A mice 
and that this effect can be reversed by administration of 17β-oes-
tradiol (Choi et al., 2008), a compound which can also inhibit 
P2X7 activation (Cario-Toumaniantz et al., 1998). Whilst, these 
Mutant  human superoxide dismutase 1 
(SOD1G93A) transgenic mice were injected in-
traperitoneally (i.p.) with BBG from each day 
(d) as indicated (blue bars) or with respective 
saline-based diluent (not shown) to end-point. 
Mice were assessed for weight loss, clinical 
score, motor coordination and survival as de-
scribed in the respective studies. Disease onset 
was defined as: first signs of tremor and/or hind 
limb motor deficits*; or 10% decline in rotarod 
performance†. Arrows represent improved (↑) 
or delayed (↓) clinical parameters. In two stud-
ies, differences in some clinical parameters were 
observed only in male (♂) or female (♀) mice.
Figure 1 P2X7 antagonism with Brilliant Blue G (BBG) can reduce amyotrophic lateral sclerosis (ALS) progression in mice.
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observations do not completely reconcile the gender differences 
observed between the pre-clinical trials with BBG in SOD1G93A 
mice (Cervetto et al., 2013; Apolloni et al., 2014; Bartlett et al., 
2017), they do suggest possible interactions between P2X7 and 
17β-oestradiol, which may influence treatment design and dis-
ease outcomes in ALS.
Gender differences aside, consideration of the pre-clinical tri-
als with BBG (Cervetto et al., 2013; Apolloni et al., 2014; Bart-
lett et al., 2017) along with the P2X7 ablation study (Apolloni et 
al., 2013) indicate that P2X7 antagonism may be of most thera-
peutic benefit when treatment commences during late pre-onset 
or early onset. However in the absence of suitable biomarkers to 
predict disease onset and given that the average time to diagno-
sis is 10–12 months in humans (Mathis et al., 2017), the poten-
tial application of P2X7 antagonism in ALS is currently limited. 
Thus, given the current knowledge about ALS in humans, future 
pre-clinical studies of P2X7 antagonism in the SOD1G93A mu-
rine model of ALS would be best served with drug treatments 
commencing at disease onset to translate any therapeutic bene-
fits observed in mice to people with ALS. Moreover, pre-clinical 
studies of P2X7 antagonism are required in other transgenic 
mouse models of ALS, such as TAR DNA-binding protein 43 
kDa (TDP-43) or C9Orf72 (Mathis et al., 2017), to determine 
if this approach has therapeutic benefits in ALS associated with 
molecular events other than mutant SOD1.
A limitation of pre-clinical trials with BBG in SOD1G93A mice 
(and other murine models of disease) is that this compound is 
not specific for P2X7. BBG can impair murine P2X7 with a half 
maximal inhibitory concentration of 2 µM (Bartlett et al., 2013), 
but this compound can also inhibit other channels including 
murine neuronal voltage-gated sodium channels at similar 
concentrations to murine P2X7 (Jo and Bean, 2011). Despite 
this caveat, BBG has been a well-recognized P2X7 antagonist 
since the year 2000, and has been the most widely used P2X7 
antagonist in vivo to date since its first use almost a decade ago 
in rodents models of multiple sclerosis, Alzheimer’s disease, 
Huntington’s disease or spinal cord injury (Bhattacharya and 
Biber, 2016). Nonetheless, future studies exploring P2X7 antag-
onism in ALS should consider using specific P2X7 antagonists, 
many of which are inhibitory at concentrations lower than that 
of BBG (Bhattacharya and Biber, 2016).
An emerging limitation of pre-clinical trials with BBG in 
SOD1G93A mice is whether this compound can cross an intact 
blood-brain barrier. In the absence of blood-brain barrier dam-
age, BBG demonstrates no significant occupancy of rat brain 
P2X7, whilst the brain to plasma ratio of BBG may be as low as 
0.0065, which is well below a target ratio of 0.2 or more (Bhat-
tacharya and Biber, 2016). Consistent with these findings, in 
SOD1G93A mice treated with BBG 3 times per week for up to 90 
days (Bartlett et al., 2017), we observed no blue coloration of 
the brains or spinal cords either macroscopically or microscop-
ically, despite extensive blue coloration of the skin macroscop-
ically, and of the livers and spleens microscopically (Bartlett R, 
Sluyter R, Yerbury JJ, unpublished). Thus, pre-clinical studies 
with P2X7 antagonists that can cross the blood-brain barrier 
(Bhattacharya and Biber, 2016) may be required to determine if 
P2X7 antagonism is of therapeutic benefit in ALS.
Our recent study (Bartlett et al., 2017) combined with studies 
by others (Cervetto et al., 2013; Apolloni et al., 2014) show that 
P2X7 antagonism has therapeutic benefits in SOD1G93A mice, 
but the observed gender differences between these studies re-
main unexplained. Nevertheless these studies suggest that P2X7 
may play a role in ALS progression, which is supported by other 
observations in rodents and humans with ALS (Volonte et al., 
2016). However, much work is required to ascertain a potential-
ly complex role of this receptor in this multifaceted, currently 
incurable neurodegenerative disorder, and to determine if P2X7 
represents a realistic therapeutic target in people with ALS.
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